

BioNexus Accelerator

Powered by the Center for Biotechnology

The BioNexus Accelerator works with founder-led executive teams who want to advance their companies from early technical validation toward Seed and Series A readiness without losing time or focus. The program is designed to reduce execution risk by aligning applied research, infrastructure pathways, and advisory input around the specific milestones investors and partners will underwrite.

The Center for Biotechnology (CfB) is a New York State–designated Center of Advanced Technology located at Stony Brook University. The Center works alongside founders, advisors, investors, and industry partners to help navigate critical development and commercialization steps tied to value inflection milestones.

Through its location at Stony Brook University, CfB connects companies to incubators and established strengths in data science, computation, engineering, chemistry, biomedical research, and clinical medicine. Sponsored research pathways and industry partnerships enable teams to engage world-class infrastructure, expertise, and talent in support of company progress, consistent with institutional policies and processes.

HOW BIONEXUS ACCELERATES COMPANIES

BioNexus is designed for executive teams who want to pressure-test their most consequential assumptions early, before scaling execution.

The program is structured around deliberate advisor engagement tied to specific, time-bound decisions rather than general feedback.

Program support emphasizes decision quality, pacing, and alignment across technical, clinical, and payer considerations. This operating model supports disciplined execution while enabling executive teams to systematically evaluate assumptions that inform subsequent development and commercialization steps.

WHAT SUCCESS MEANS AT BIONEXUS

At the pre-seed stage, success is defined by knowing which risks actually matter and having a clear, evidence backed execution plan to address them. BioNexus is structured to help executive teams sequence the critical risks that must be addressed before a Seed or Series A round, so the next investor or partner can engage without requiring a strategic reset.

By program close, success means the executive team exits with a set of externally credible, diligence, ready inflection milestones, owned by the company, supported by evidence, and aligned with how the next round will actually be evaluated.

For investors and partners, this means engaging with teams that have already pressure-tested assumptions and clarified proof points.



Program Structure

INVESTOR & PARTNER READINESS

The BioNexus program is designed so that, by program close, the executive team has clarified its execution plan and codified that clarity into a defined set of company-defining outputs to enable productive investor and partner meetings:

- Target Product Profile (TPP), supported by relevant validation data
- Strategic operating plan spanning pre-seed through Seed
- Development of Gantt chart mapping milestones, dependencies, and critical path
- Pitch materials, including a socialization deck and a diligence-ready deck

GETTING STARTED

Each company establishes a version 0 (VO) baseline across core materials:

- Current pitch deck
- Pre-seed operating plan (Feb–June 2026)
- Risk reduction milestones to be addressed during BioNexus Program
- Target Product Profile (TPP), including intended use, target population, and labeling claims

VO captures the team's current position. It is not expected to be complete or correct, its value is making assumptions explicit so they can be tested and refined through execution.


EXECUTION CADENCE

The cadence is designed to compress time—turning months of execution into weeks of clarity.

- Two Board of Advisors meetings
- Weekly Entrepreneurs-in-Residence check-ins
- Nine focused market validation sprints
- Dedicated office hours for Regulatory and VC.

Structured working sessions support core execution areas, including market validation, Target Product Profile development, pitch narrative, and partnering strategy.

Program engagement includes participation in BIO and the Life Sciences Summit Investor Day.



Program Structure

Phase 1 (Pre-Board): VO baseline + top 3 adoption risks + sprint plan

Phase 2 (Board 1): milestone selection + proof-point prioritization

Phase 3 (Inter-board): sprint evidence + updated TPP/pitch narrative

Phase 4 (Board 2): direction lock + partner & investor narrative confirmation

Phase 5 (Partnering/ARAD): ARAD proposal + target lists + 90-day plan

BioNexus provides two distinct advisory roles to support disciplined execution.

Entrepreneurs-in-Residence (EIRs) engage with executive teams to surface the most consequential questions facing the business and to frame near-term execution around resolving them. This engagement is intended to produce decision-relevant data and signals to inform executive judgment.

ADVISOR STRUCTURE

Board of Advisors (BoA) meetings provide a forum for discussion at the appropriate level of altitude. These meetings focus on whether execution is addressing the risks that matter most at the company's current stage and whether progress supports the next value-defining inflection.

Between advisory meetings, the company's execution centers on targeted sprints designed to generate the specific signals required for informed decision-making. Across advisory cycles, priorities become more focused, and execution remains aligned with value creation. Advisors inform decisions; final judgment and accountability remain with the company's executive team.



Program Structure

ENTREPRENEUR IN RESIDENCE

EIRs are experienced operators who work alongside executive teams as independent thinking partners, not decision makers. They bring practical experience across product development, clinical strategy, market adoption, and capitalization, and provide an objective perspective as teams navigate critical decisions.

EIR weekly Office Hour engagement focuses on pressure-testing execution plans across the Target Product Profile, regulatory pathway, manufacturing considerations, medical access, and go-to-market strategy. The intent is to strengthen decision quality while decision ownership remains with the executive team.

Working with Entrepreneurs-in-Residence

EIR meetings are organized around active decisions. Teams frame discussions with a concise written brief that establishes the decision under consideration, the trade-offs that make it non-obvious, and the team's current position. The brief also identifies the specific question where experience-based perspective is most valuable.


This format keeps discussions focused on judgment and execution, rather than background context, and ensures advisory time is applied to the choices that matter most to the executive team.

BOARD OF ADVISORS

Board of Advisors meetings are designed to support executive judgment at the appropriate level of altitude. Discussion centers on the decisions facing the business and the trade-offs that matter most, rather than on status updates.

Board discussions are framed by a concise, non confidential deck that provides sufficient context to enable productive dialogue. Materials focus on the questions the executive team is working through, rather than on comprehensive reporting.

Input from the Board is considered alongside other signals and perspectives. The executive team determines how that input informs direction and priorities. Entrepreneurs-in-Residence and the Managing Director are available for follow-up discussions through office hours.





Program Structure

KEY PROGRAM TERMS

BioNexus works with pre-seed to Seed stage deep technology life science companies leveraging SBU research and clinical infrastructure to reach inflection milestones

The program takes no equity and charges no fees.

Program duration is 5 months.

Applied Research & Development (ARAD)

ARAD is a matching non-dilutive execution instrument designed to fund the specific experiment or translational step that advances a company through a value inflection milestone. It is not general funding. ARAD is earned through execution readiness and is deployed to retire a clearly articulated technical or translational risk.

Participating companies in BioNexus may apply for ARAD support to fund a defined body of work conducted in collaboration with Stony Brook University. Awards are competitive and based on merit, readiness, and the decision value of the proposed work. ARAD projects are scoped around explicit objectives, milestones, and outputs aligned to the company's next inflection point. The intent is to generate decisive signal, changing the quality of the conversation founders have with their next investor or partner.

BIONEXUS STAFF

BioNexus staff support program execution through coordinated access to relevant stakeholders, operational resources, and program events.

This includes engagement with clinical, research, and industry networks; coordination of laboratory, core facility, and external provider resources; and execution of program convenings, including BIO and the Life Sciences Summit.

